Drugs / Elraglusib
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06896188 | Sep 2025 → Mar 2028 expected | pancreatic adenocarcinoma | Anwaar Saeed | Recruiting | No outcome recorded |
| Phase 1 | NCT04239092 | Jun 2020 → Jul 2025 | diffuse intrinsic pontine glioma, neuroblastoma, pediatric lymphoma, pediatric meningioma +1 | Actuate Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07714395 | Oct 2026 → Jul 2029 expected | cancer | Actuate Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 28 trials · 1 met primary | ||||||
| Phase 2 | NCT04832438 | Dec 2030 → Jun 2033 | adenoid cystic carcinoma, salivary gland carcinoma | Actuate Therapeutics Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05077800 | Mar 2022 → Dec 2026 expected | pancreatic adenocarcinoma | Colin D. Weekes, M.D., PhD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05116800 | Mar 2022 → Aug 2025 | Ewing sarcoma of bone, angiosarcoma, leiomyosarcoma, liposarcoma +6 | Brown University | Withdrawn | No outcome recorded |
| Phase 2 | NCT05239182 | Jan → Dec 2022 | pancreatic adenocarcinoma | Anwaar Saeed | Terminated | No outcome recorded |
| Phase 2 | NCT05010629 | Sep 2021 → Feb 2025 overdue | metastatic malignant neoplasm, salivary gland adenoid cystic carcinoma | Glenn J. Hanna | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04906876 | Sep 2021 → Jul 2022 | angiosarcoma, leiomyosarcoma, liposarcoma, myxofibrosarcoma +4 | Brown University | Withdrawn | No outcome recorded |
| Phase 2 | NCT04218071 | Aug 2020 → Oct 2022 | myelofibrosis | Actuate Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03678883 | Jan 2019 → Jun 2026 overdue | T lymphoblastic leukemia/lymphoma, bone cancer, breast neoplasm, colorectal neoplasm +8 | Actuate Therapeutics Inc. | Active not recruiting | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elraglusib | “Elraglusib (9-ING-41) is a specific small-molecule inhibitor of GSK-3β with clinical activity in patients with advanced cancers, including a patient with refractory melanoma...” PMID 36104795 ↗ Sep 2022 |
| Known as | 9-ING-41 | “Drug: 9-ING-41” NCT05116800 ↗ |
| Action | Inhibit | “9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3β inhibitor with significant pre-clinical antitumor activity.” NCT03678883 ↗ |
| Modality | Small molecule | “9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3β inhibitor with significant pre-clinical antitumor activity.” NCT03678883 ↗ |
| Route | Intravenous | “9-ING-41 will be administered intravenously over 60 minutes.” NCT03678883 ↗ |
| Target | GSK3B | “9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3β inhibitor with significant pre-clinical antitumor activity.” NCT03678883 ↗ |